Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coeptis Therapeutics Holdings (COEP) EBITDA Margin (2021 - 2025)

Coeptis Therapeutics Holdings (COEP) has 2 years of EBITDA Margin data on record, last reported at 1043.22% in Q3 2025.

  • For Q3 2025, EBITDA Margin changed N/A year-over-year to 1043.22%; the TTM value through Sep 2025 reached 2638.23%, changed N/A, while the annual FY2021 figure was 18727.91%, N/A changed from the prior year.
  • EBITDA Margin reached 1043.22% in Q3 2025 per COEP's latest filing, up from 2252.94% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 82.0% in Q4 2021 and bottomed at 6452.56% in Q1 2025.